Commitment To Oncology
This is Living with Cancer
Scheduled Events
Symposium
Guiding Light: Practical Perspectives of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
Slot: 10 | 12 May 2023 18:30 – 19:30 CEST
Add to Calendar
Scientific Presentations
Presentation Title: Real-World Effectiveness of Palbociclib (Pal)
Plus an Aromatase Inhibitor (AI) vs
AI Alone in
Patients Who Have Metastatic
Breast Cancer (mBC) With Lung or Liver Metastases
Add to Calendar
Presentation Title: Using
Artificial Intelligence to Map the CDK4/6 Inhibitor Translational Biomarker Landscape
Add to Calendar
Presentation Title: Real-World
Clinical Outcomes Associated
with First-Line Palbociclib and Aromatase Inhibitor
Therapy Among Patients with HR+/HER2− Advanced Breast
Cancer in Europe
Add to Calendar
Poster Presentations
Presentation Title: Palbociclib
Presentation 427
Real-World Effectiveness of Palbociclib (Pal) Plus an Aromatase Inhibitor (AI) vs AI Alone in
Patients Who Have Metastatic Breast Cancer (mBC) With Lung or Liver Metastases
Brufsky A
Presentation Date and Time:
Friday, May 12
12:15 PM – 1:00 PM (CEST)
Presentation Title: Palbociclib
Presentation 295
Using Bioinformatics and Artificial Intelligence (AI) to Map the Cyclin-dependent Kinase 4/6
Inhibitor (CDK4/6i) Translational Biomarker Landscape
Wager K
Presentation Date and Time:
Friday, May 12
12:15 PM – 1:00 PM (CEST)
Presentation Title: Palbociclib
Presentation 417
Real-World Clinical Outcomes Associated with First-Line Palbociclib and Aromatase Inhibitor
Therapy Among Patients with HR+/HER2− Advanced Breast Cancer in Europe
Oikonomidou O
Presentation Date and Time:
Friday, May 12
12:15 PM – 1:00 PM (CEST)
Presentation Title: Palbociclib
Presentation 430
Treatment Patterns and Comorbidities in Patients With HR+/HER2– MBC: A Real-World
Study in Five European Countries
Mahtani R
Presentation Date and Time:
Friday, May 12
12:15 PM – 1:00 PM (CEST)
Presentation Title: ARV-471
Presentation 366
TACTIVE-N: open-label, randomized, noncomparative neoadjuvant phase 2 study of
ARV-471, a PROteolysis TArgeting Chimera (PROTAC) estrogen receptor (ER) degrader, or
anastrozole in postmenopausal women with ER+/human epidermal growth factor receptor 2
(HER2)– localized breast cancer
Fasching P
Presentation is supported by Pfizer and ARVINAS.
Presentation Date and Time:
Friday, May 12
12:15 PM – 1:00 PM (CEST)
Presentation Title: ARV-471
Presentation 409
VERITAC update: phase 2 study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC)
estrogen receptor (ER) degrader in ER+/human epidermal growth factor receptor 2 (HER2)–
advanced breast cancer
Hurvitz S
Presentation is supported by Pfizer and ARVINAS.
Presentation Date and Time:
Friday, May 12
12:15 PM – 1:00 PM (CEST)
Presentation Title: ARV-471
Presentation 459
TACTIVE-E: phase 1b study of ARV-471, a PROteolysis TArgeting Chimera (PROTAC)
estrogen receptor (ER) degrader, in combination with everolimus in ER+/human epidermal
growth factor receptor 2 (HER2)– advanced breast cancer
Philipovskiy A
Presentation is supported by Pfizer and ARVINAS.
Presentation Date and Time:
Friday, May 12
12:15 PM – 1:00 PM (CEST)
Presentation Title: ARV-471
Presentation 460
VERITAC-2: a global, randomized phase 3 study of ARV-471, a PROteolysis TArgeting
Chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human
epidermal growth factor receptor 2 (HER2)– advanced breast cancer
Hamilton E
Presentation is supported by Pfizer and ARVINAS.
Presentation Date and Time:
Friday, May 12
12:15 PM – 1:00 PM (CEST)
